Quantcast
Last updated on April 21, 2014 at 9:29 EDT

Latest Glycated hemoglobin Stories

2012-06-22 10:46:38

Preventing diabetes or delaying its onset has been thought to stave off cognitive decline – a connection strongly supported by the results of a 9-year study led by researchers at the University of California, San Francisco (UCSF) and the San Francisco VA Medical Center. Earlier studies have looked at cognitive decline in people who already had diabetes. The new study is the first to demonstrate that the greater risk of cognitive decline is also present among people who develop...

2012-06-21 14:21:58

FRESNO, Calif., June 21, 2012 /PRNewswire/ -- New research debuted at the American Diabetes Association's 72nd Annual Scientific Session suggests eating raisins three times a day may significantly lower postprandial (post-meal) glucose levels when compared to common alternative snacks of equal caloric value. The study was conducted at the Louisville Metabolic and Atherosclerosis Center (L-MARC) by lead researcher, Harold Bays, MD, medical director and president of L-MARC. To view the...

2012-06-19 09:30:04

Among well-functioning older adults without dementia, diabetes mellitus (DM) and poor glucose control among those with DM are associated with worse cognitive function and greater cognitive decline, according to a report published Online First by Archives of Neurology, a JAMA Network publication. Findings from previous studies have suggested an association between diabetes mellitus and an increased risk of cognitive impairment and dementia, including Alzheimer disease, but this association...

2012-06-11 10:24:30

PHILADELPHIA, June 11, 2012 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Boehringer Ingelheim today announced results from two Phase II studies of their investigational novel basal insulin analog, LY2605541. Results of the type 1 diabetes study showed that LY2605541 was associated with greater improvements of glycemic control (lowering blood sugar levels) than insulin glargine. In the type 2 diabetes study, the primary measure showed that LY2605541 and insulin glargine had similar...

2012-06-09 10:22:19

RIDGEFIELD, Conn. and INDIANAPOLIS, June 9, 2012 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company (NYSE: LLY) today announced results from a post-hoc analysis, which explored the clinical effect of linagliptin on albuminuria in patients with type 2 diabetes who had early diabetic nephropathy (renal disease). The primary endpoint of the analysis was changes to the urinary albumin-to-creatinine ratio (UACR), which is a measure of renal function in patients...

2012-06-09 06:21:27

RIDGEFIELD, Conn. and INDIANAPOLIS, June 9, 2012 /PRNewswire/-- Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company (NYSE: LLY) presented results that showed empagliflozin (BI 10773), alone or as an add-on to metformin, reduced hemoglobin A1c (HbA1c or A1C) levels, fasting plasma glucose (FPG) levels and body weight when given to adults with type 2 diabetes for up to 90 weeks.[1] A1C is measured in people with diabetes to provide an index of blood glucose control for the...

2012-06-09 06:21:21

RIDGEFIELD, Conn. and INDIANAPOLIS, June 9, 2012 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company (NYSE: LLY) presented results from two randomized phase 3 clinical trials and a post-hoc analysis for linagliptin at the American Diabetes Association's (ADA's) 72nd Scientific Sessions®. The new studies provide additional data evaluating the efficacy and safety of linagliptin (alone or in combination with other diabetes therapies) in adults with type 2...

2012-06-09 06:21:20

PHILADELPHIA, June 9, 2012 /PRNewswire/ -- Metabolic Solutions Development Company, LLC (MSDC) presented Phase 2b results for MSDC-0160 today at the 72nd Scientific Sessions of the American Diabetes Association. The data showed this novel once-a-day oral insulin sensitizer, the first in a new class of therapeutic agents called mTOT Modulators(TM), met the study's primary endpoint of significantly reducing fasting plasma glucose (FPG) in patients diagnosed with type 2 diabetes, and...

2012-06-08 11:00:15

Studies suggest greater danger, but risk appears to vary by definition Millions of pre-diabetic Americans may be at increased risk of future stroke, say researchers at the University of California, San Diego School of Medicine in a new meta-analysis of epidemiological studies, but the precise degree of that threat is confounded by differing medical definitions and factors that remain unknown or unmeasured. "The immediate implication of our findings is that people with pre-diabetes...

2012-06-06 06:25:47

SHERWOOD, Ore., June 6, 2012 /PRNewswire/ -- Entia Biosciences, Inc. (OTCBB: ERGO) (ENTIA) announced today that it has commenced an exploratory study at a nationally recognized teaching/research hospital on the West Coast to evaluate the clinical tolerability and potential therapeutic benefits of ErgoD2(TM) Hemo in patients being treated for Diabetes and Anemia. A second international site, in a region where diabetes has become epidemic in proportions, has also agreed to participate in the...